Australia's premier life science investment event, AusBioInvest 2024, is in Melbourne today.
The one-day event welcomes more than 260 delegates from Australia's life science companies, local and global investors, including venture capital firms, private equity firms, individuals, research analysts and brokers, industry executives, and major global stakeholders.
AusBiotech CEO Rebekah Cassidy said Australia's biggest week in biotech is officially here, with AusBioInvest followed by the three-day AusBiotech 2024 national conference.
"AusBioInvest is just one way that AusBiotech continues to ensure our investment programmes are designed to the evolving needs of our members at all stages of capital raising, with a laser focus on creating meaningful connections," she said.
The AusBioInvest programme begins with an opening keynote by Dr Eric Shiozaki, Partner at DCVC Bio, exploring the transformative role of AI and technology in biotech and sharing valuable perspectives on what drives success from an investor’s viewpoint.
This will be followed by panels featuring Sarah Meibusch, Partner at OneVentures, who will unpack investment trends and diverse funding options—public, private, debt, and equity, and Rhenu Bhuller, AusBiotech's Global Investment Lead, who will join experts Matt McNamara of Horizon 3 Healthcare and Bianca Ogden of Platinum Asset Management to discuss how investors and founders can effectively collaborate to drive biotech innovation.
The presentations at AusBioInvest, featuring 23 private and listed Australian biotechnology companies, represent a significant opportunity for investors and potential partners to connect directly with companies seeking funding and collaborative development.
Presenting companies include Amplia Therapeutics (ASX:ATX), Arovella Therapeutics (ASX:ALA), Atticus Medical, BiomeBank, Blinklab (ASX:BB1), Cambium Bio (ASX:CMB), Carina Biotech, Chimeric Therapeutics (ASX:CHM), EBR Systems (ASX:EBR), Evithé Biotechnology, FivepHusion, Immuron (ASX:IMC), Imugene (ASX:IMU), Invion (ASX:IVX), Neurizon Therapeutics (ASX:NUZ), Neurotologix, Novapep, Nyrada (ASX:NYR), Esfam Biotech, Polyactiva, Servatus, Syntara (ASX:SNT) and Vaxxas.
"Part of AusBiotech’s role is knowledge sharing and connection building including with the investment community. Our ‘Invest’ events help great Australian companies to attract capital while assisting investors in connecting with innovative Australian companies that may offer high-value returns,” said Ms Cassidy.
"We are proud of our work to put Australia's homegrown innovation on the global stage with local and international investors.”